Phase 2 Study Of Cabozantinib (XL184) For Plexiform Neurofibromas In Subjects With Neurofibromatosis Type 1 Age 16 Years Or Greater

Brief description of study

If you have been diagnosed with Neurofibromatos Type 1 (NF-1), a condition affecting the nervous system, and plexiform neurofibroma (a type of rare, noncancerous tumor) you may qualify to participate in a study evaluating the drug Cabozantinib as a treatment for Neurofibromatos Type 1 (NF-1). The main goal of this phase II study is to test the effectiveness of Cabozantinib as a treatment for Neurofibromatosis Type 1 patients with plexiform neurofibromas.


Clinical Study Identifier: s14-00969
ClinicalTrials.gov Identifier: NCT02101736
Principal Investigator: Jeffrey C Allen.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.